Cargando…
The anticipating value of PLK1 for diagnosis, progress and prognosis and its prospective mechanism in gastric cancer: a comprehensive investigation based on high-throughput data and immunohistochemical validation
Polo-like kinase 1 (PLK1) is a multi-functional protein and its aberrant expression is a driver of cancerous transformation and progression. To increase our understanding of the clinical value and potential molecular mechanism of PLK1 in gastric cancer (GC), we performed this comprehensive investiga...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5696199/ https://www.ncbi.nlm.nih.gov/pubmed/29190933 http://dx.doi.org/10.18632/oncotarget.21438 |
_version_ | 1783280398562754560 |
---|---|
author | Lin, Peng Xiong, Dan-Dan Dang, Yi-Wu Yang, Hong He, Yun Wen, Dong-Yue Qin, Xin-Gan Chen, Gang |
author_facet | Lin, Peng Xiong, Dan-Dan Dang, Yi-Wu Yang, Hong He, Yun Wen, Dong-Yue Qin, Xin-Gan Chen, Gang |
author_sort | Lin, Peng |
collection | PubMed |
description | Polo-like kinase 1 (PLK1) is a multi-functional protein and its aberrant expression is a driver of cancerous transformation and progression. To increase our understanding of the clinical value and potential molecular mechanism of PLK1 in gastric cancer (GC), we performed this comprehensive investigation. A total of 25 datasets and 12 publications were finally incorporated. Additional immunohistochemistry was conducted to validate the expression pattern of PLK1 in GC. The pooled standard mean deviation (SMD) indicated that PLK1 mRNA was up-regulated in GC (SMD=1.21, 95% CI: 0.65-1.77, P< 0.001). Similarly, the pooled odds ratio (OR) revealed that PLK1 protein was overexpressed in GC compared with normal gastric tissue (OR=12.12, 95% CI: 5.41-27.16, P<0.001). The area under the curve (AUC) of the summary receiver operating characteristic (SROC) curve was 0.86. Furthermore, our results demonstrated that GC patients with PLK1 overexpression were significantly associated with unfavorable overall survival (HR =1.54, 95% CI: 1.30–1.83, P<0.001), lymph node metastasis (OR = 1.78, 95% CI: 1.13–2.80, P=0.013) and advanced TNM stage (OR=1.48, 95% CI: 1.02-2.15, P=0.038). Altogether, 100 similar genes were identified by Gene Expression Profiling Interactive Analysis (GEPIA) and further with gene-set enrichment analysis. These genes were related to gene ontology (GO) terms and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways relevant to the cell cycle. Gene set enrichment analysis (GSEA) indicated that PLK1 is associated with various cancer-related pathways. Collectively, this study suggests that PLK1 overexpression could play vital roles in the carcinogenesis and deterioration of GC via regulating tumor-related pathways. |
format | Online Article Text |
id | pubmed-5696199 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | Impact Journals LLC |
record_format | MEDLINE/PubMed |
spelling | pubmed-56961992017-11-29 The anticipating value of PLK1 for diagnosis, progress and prognosis and its prospective mechanism in gastric cancer: a comprehensive investigation based on high-throughput data and immunohistochemical validation Lin, Peng Xiong, Dan-Dan Dang, Yi-Wu Yang, Hong He, Yun Wen, Dong-Yue Qin, Xin-Gan Chen, Gang Oncotarget Research Paper Polo-like kinase 1 (PLK1) is a multi-functional protein and its aberrant expression is a driver of cancerous transformation and progression. To increase our understanding of the clinical value and potential molecular mechanism of PLK1 in gastric cancer (GC), we performed this comprehensive investigation. A total of 25 datasets and 12 publications were finally incorporated. Additional immunohistochemistry was conducted to validate the expression pattern of PLK1 in GC. The pooled standard mean deviation (SMD) indicated that PLK1 mRNA was up-regulated in GC (SMD=1.21, 95% CI: 0.65-1.77, P< 0.001). Similarly, the pooled odds ratio (OR) revealed that PLK1 protein was overexpressed in GC compared with normal gastric tissue (OR=12.12, 95% CI: 5.41-27.16, P<0.001). The area under the curve (AUC) of the summary receiver operating characteristic (SROC) curve was 0.86. Furthermore, our results demonstrated that GC patients with PLK1 overexpression were significantly associated with unfavorable overall survival (HR =1.54, 95% CI: 1.30–1.83, P<0.001), lymph node metastasis (OR = 1.78, 95% CI: 1.13–2.80, P=0.013) and advanced TNM stage (OR=1.48, 95% CI: 1.02-2.15, P=0.038). Altogether, 100 similar genes were identified by Gene Expression Profiling Interactive Analysis (GEPIA) and further with gene-set enrichment analysis. These genes were related to gene ontology (GO) terms and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways relevant to the cell cycle. Gene set enrichment analysis (GSEA) indicated that PLK1 is associated with various cancer-related pathways. Collectively, this study suggests that PLK1 overexpression could play vital roles in the carcinogenesis and deterioration of GC via regulating tumor-related pathways. Impact Journals LLC 2017-09-30 /pmc/articles/PMC5696199/ /pubmed/29190933 http://dx.doi.org/10.18632/oncotarget.21438 Text en Copyright: © 2017 Lin et al. http://creativecommons.org/licenses/by/3.0/ This article is distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0/) (CC-BY), which permits unrestricted use and redistribution provided that the original author and source are credited. |
spellingShingle | Research Paper Lin, Peng Xiong, Dan-Dan Dang, Yi-Wu Yang, Hong He, Yun Wen, Dong-Yue Qin, Xin-Gan Chen, Gang The anticipating value of PLK1 for diagnosis, progress and prognosis and its prospective mechanism in gastric cancer: a comprehensive investigation based on high-throughput data and immunohistochemical validation |
title | The anticipating value of PLK1 for diagnosis, progress and prognosis and its prospective mechanism in gastric cancer: a comprehensive investigation based on high-throughput data and immunohistochemical validation |
title_full | The anticipating value of PLK1 for diagnosis, progress and prognosis and its prospective mechanism in gastric cancer: a comprehensive investigation based on high-throughput data and immunohistochemical validation |
title_fullStr | The anticipating value of PLK1 for diagnosis, progress and prognosis and its prospective mechanism in gastric cancer: a comprehensive investigation based on high-throughput data and immunohistochemical validation |
title_full_unstemmed | The anticipating value of PLK1 for diagnosis, progress and prognosis and its prospective mechanism in gastric cancer: a comprehensive investigation based on high-throughput data and immunohistochemical validation |
title_short | The anticipating value of PLK1 for diagnosis, progress and prognosis and its prospective mechanism in gastric cancer: a comprehensive investigation based on high-throughput data and immunohistochemical validation |
title_sort | anticipating value of plk1 for diagnosis, progress and prognosis and its prospective mechanism in gastric cancer: a comprehensive investigation based on high-throughput data and immunohistochemical validation |
topic | Research Paper |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5696199/ https://www.ncbi.nlm.nih.gov/pubmed/29190933 http://dx.doi.org/10.18632/oncotarget.21438 |
work_keys_str_mv | AT linpeng theanticipatingvalueofplk1fordiagnosisprogressandprognosisanditsprospectivemechanismingastriccanceracomprehensiveinvestigationbasedonhighthroughputdataandimmunohistochemicalvalidation AT xiongdandan theanticipatingvalueofplk1fordiagnosisprogressandprognosisanditsprospectivemechanismingastriccanceracomprehensiveinvestigationbasedonhighthroughputdataandimmunohistochemicalvalidation AT dangyiwu theanticipatingvalueofplk1fordiagnosisprogressandprognosisanditsprospectivemechanismingastriccanceracomprehensiveinvestigationbasedonhighthroughputdataandimmunohistochemicalvalidation AT yanghong theanticipatingvalueofplk1fordiagnosisprogressandprognosisanditsprospectivemechanismingastriccanceracomprehensiveinvestigationbasedonhighthroughputdataandimmunohistochemicalvalidation AT heyun theanticipatingvalueofplk1fordiagnosisprogressandprognosisanditsprospectivemechanismingastriccanceracomprehensiveinvestigationbasedonhighthroughputdataandimmunohistochemicalvalidation AT wendongyue theanticipatingvalueofplk1fordiagnosisprogressandprognosisanditsprospectivemechanismingastriccanceracomprehensiveinvestigationbasedonhighthroughputdataandimmunohistochemicalvalidation AT qinxingan theanticipatingvalueofplk1fordiagnosisprogressandprognosisanditsprospectivemechanismingastriccanceracomprehensiveinvestigationbasedonhighthroughputdataandimmunohistochemicalvalidation AT chengang theanticipatingvalueofplk1fordiagnosisprogressandprognosisanditsprospectivemechanismingastriccanceracomprehensiveinvestigationbasedonhighthroughputdataandimmunohistochemicalvalidation AT linpeng anticipatingvalueofplk1fordiagnosisprogressandprognosisanditsprospectivemechanismingastriccanceracomprehensiveinvestigationbasedonhighthroughputdataandimmunohistochemicalvalidation AT xiongdandan anticipatingvalueofplk1fordiagnosisprogressandprognosisanditsprospectivemechanismingastriccanceracomprehensiveinvestigationbasedonhighthroughputdataandimmunohistochemicalvalidation AT dangyiwu anticipatingvalueofplk1fordiagnosisprogressandprognosisanditsprospectivemechanismingastriccanceracomprehensiveinvestigationbasedonhighthroughputdataandimmunohistochemicalvalidation AT yanghong anticipatingvalueofplk1fordiagnosisprogressandprognosisanditsprospectivemechanismingastriccanceracomprehensiveinvestigationbasedonhighthroughputdataandimmunohistochemicalvalidation AT heyun anticipatingvalueofplk1fordiagnosisprogressandprognosisanditsprospectivemechanismingastriccanceracomprehensiveinvestigationbasedonhighthroughputdataandimmunohistochemicalvalidation AT wendongyue anticipatingvalueofplk1fordiagnosisprogressandprognosisanditsprospectivemechanismingastriccanceracomprehensiveinvestigationbasedonhighthroughputdataandimmunohistochemicalvalidation AT qinxingan anticipatingvalueofplk1fordiagnosisprogressandprognosisanditsprospectivemechanismingastriccanceracomprehensiveinvestigationbasedonhighthroughputdataandimmunohistochemicalvalidation AT chengang anticipatingvalueofplk1fordiagnosisprogressandprognosisanditsprospectivemechanismingastriccanceracomprehensiveinvestigationbasedonhighthroughputdataandimmunohistochemicalvalidation |